The Cambridge spinout is commercialising research into better techniques for extracting quality stem cells, having raised a reported $464,000 in seed funding.

Elpis Biomed, a UK-based stem cell spinout from University of Cambridge, raised an undisclosed amount of seed funding on Thursday, reported by Business Weekly as being worth £350,000 ($464,000).

The money was provided by a group of angel investors, led by Jonathan Milner, with co-investments from Darrin Disley, Weslie Janeway and Nikolaus Starzacher.

The spinout was incorporated in November 2016 as Cambridge Cell Technologie before being rebranded in January 2017. Elpis Biomed is commercialising the Opti-Ox platform, developed at Cambridge…